These links are provided as a convenience and is not an endorsement by Allena Pharmaceuticals of the site's content. Allena does not review or control the content of non-Allena websites.

Publications

Recently Added

Enteric Hyperoxaluria in Chronic Pancreatitis. Demoulin N et al. Medicine 2017.

Results of a Phase 2 Randomized Controlled Trial of ALLN-177 in Patients wth Secondary Hyperoxaluria. Nigwekar S. ASN Kidney Week 2017.

PDF

ALLN-177, a Novel Oral Enzyme Therapy, Reduces Urinary Oxalate Excretion and Plasma Oxalate in a Porcine Dietary Model of Severe Hyperoxaluria. Grujic D et al. ASN Kidney Week 2017.

PDF

ALLN-177

Results of a Phase 2 Randomized Controlled Trial of ALLN-177 in Patients wth Secondary Hyperoxaluria. Nigwekar S. ASN Kidney Week 2017.

ALLN-177, a Novel Oral Enzyme Therapy, Reduces Urinary Oxalate Excretion and Plasma Oxalate in a Porcine Dietary Model of Severe Hyperoxaluria. Grujic D et al. ASN Kidney Week 2017.

A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme. Langman CB et al. Am J Nephrol 2016.

ALLN-177 Reduces Hyperoxaluria in a Porcine Model of Secondary Hyperoxaluria (2°HO) Induced by a Human-like Oxalate Rich Diet. Grujic D et al. J Urol 2016.

Hyperoxaluria Is Reduced and Nephrocalcinosis Prevented with an Oxalate-Degrading Enzyme in Mice with Hyperoxaluria. Grujic D et al. Am J Nephrol 2009.

Hypereoxaluria and Kidney Disorders

The Cause of Idiopathic Calcium Stone Disease: Hypercalciuria or Hyperoxaluria? Robertson WG, Peacock M. Nephron 1980.

Comparison of Two Diets for the Prevention of Recurrent Stones in Idiopathic Hypercalciuria. Borghi L et al. N Engl J Med 2002.

The Most Important Metabolic Risk Factors in Recurrent Urinary Stone Formers. Parvin M et al. Urol J 2011.

24-h Uric Acid Excretion and the Risk of Kidney Stones. Curhan GC et al.  Kidney Int 2008.

Results of Long-term Treatment with Orthophosphate and Pyridoxine in Patients with Primary Hyperoxaluria. Milliner DS et al. N Engl J Med 1994.

Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure.  Zhao F et al. Clin J Am Soc Nephrol 2016.

Risk of Nephrolithiasis, Hyperoxaluria, and Calcium Oxalate Supersaturation Increased after Roux-en-Y Gastric Bypass Surgery: A Systematic Review and Meta-analysis. Upala S et al. Surg Obes Relat Dis 2016.

Enteric Hyperoxaluria: An Important Cause of End-stage Kidney Disease.  Nazzal L et al. Nephrol Dial Transplant 2016.

Enteric Hyperoxaluria in Chronic Pancreatitis. Demoulin N et al. Medicine 2017.

Oxalate Nephropathy Complicating Roux-en-Y Gastric Bypass: An Underrecognized Cause of Irreversible Renal Failure. Nasr S et al. Clin J Am Soc Nephrol 2008.

Plasma oxalate in relation to eGFR in patients with primary hyperoxaluria, enteric hyperoxaluria and urinary stone disease.  Pernipam M et al. Clin Biochem 2017.

Treatment of the Primary Hyperoxalurias: A New Chapter. Milliner, D. Kidney Int 2006.

Hyperoxaluria Background

Primary and Secondary Hyperoxaluria: Understanding the Enigma.  Bhasin B et al.  World J Nephrol 2015.

Prevalence of Hyperoxaluria in Urinary Stone Formers: Chronological and Geographic Trends and a Literature Review. Spradling K et al. J Endourol 2016.

Oxalate, Inflammasome and Progression of Kidney Disease. Ermer T et al. Curr Opin Nephro Hypertens 2016.